US-based bio-pharmaceutical company CytomX Therapeutics has initiated treatment in a Phase I/II trial (PROCLAIM-072) of CX-072 to treat patients with any type of cancer.

CX-072 is a PD-L1 designed to target Probody therapeutic as a monotherapy or in combination with Yervoy (ipilimumab) or Zelboraf (vemurafenib).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The open-label, dose-finding Phase I/II study is part of the firm's PROCLAIM (Probody Clinical Assessment In Man) programme and will evaluate tolerability and anti-cancer activity of CX-072.

CytomX Therapeutics chief medical officer Rachel Humphrey said: “Treating the first patient with CX-072 marks a key milestone as we advance our broad pipeline of innovative Probody therapeutics into clinical development within the PROCLAIM programme.

"Treating the first patient with CX-072 marks a key milestone as we advance our broad pipeline of innovative Probody therapeutics into clinical development within the PROCLAIM programme."

“Advancement of this potentially transformational treatment, derived from our Probody technology platform, would not be possible without the patients who are willing to engage with the scientific community by enrolling in clinical trials. We thank them for their participation.”

See Also:

The trial will assess the tolerance and safety of the drug in the patients primarily as combination therapy, in addition to establishing initial evidence of CX-072’s anti-cancer activity both as a monotherapy and in combination.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The firm aims to further establish a translational programme and Probody platform proof-of-concept through the Phase I/II study.

Based on its Probody technology platform, CytomX develops investigational antibody therapeutics and cancer immunotherapies against clinically validated targets.

The developed Probody therapeutics are expected to act on the tumour microenvironment to increase the tumour-targeting properties of an antibody and decrease drug activity in healthy tissues.